Medical Xpress on MSN10d
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseasesInvestigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...
9d
News-Medical.Net on MSNAsah1 gene plays key role in preventing progression of nonalcoholic fatty liver diseaseInvestigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...
The findings from the new study in The American Journal of Pathology ... to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis ...
Nonalcoholic fatty liver disease (NAFLD ... on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related cirrhosis.
In addition, histopathologic criteria for NASH were no longer found in 89. ... However, in 13.4% of patients, liver histology was unchanged - one had mild steatosis and one had cirrhosis.
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.
"Achieving statistical significance on a histology endpoint in compensated ... In turn, that "underscores the importance of treating liver fibrosis due to NASH before it progresses to cirrhosis ...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results